CompletedNCT00528905
AZD3480 for cognitive difficulties in schizophrenia
About this title
Read the official source — NCT00528905Medication studyAges 18–55United States + Canada
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 79 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateAugust 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 400
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Canada
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00528905
- Official title
Show the full official title
A Multi-Center Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase IIb Proof of Concept Study With 3 Oral Groups of AZD3480 During 12 Weeks Treatment of Cognitive Deficits in Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock, United States · Anaheim, United States · Cerritos, United States
77 more locations
- Costa Mesa, United States
- Escondido, United States
- Garden Grove, United States
- Long Beach, United States
- Los Angeles, United States
- Oceanside, United States
- Pasadena, United States
- Pico Rivera, United States
- San Diego, United States
- Santa Ana, United States
- New Britain, United States
- New Haven, United States
- Washington D.C., United States
- Boca Raton, United States
- Coral Gables, United States
- North Miami, United States
- Orlando, United States
- Tampa, United States
- Atlanta, United States
- Augusta, United States
- Marietta, United States
- Chicago, United States
- Joliet, United States
- Schaumburg, United States
- Indianapolis, United States
- New Orleans, United States
- Glen Burnie, United States
- Haverhill, United States
- Pittsfield, United States
- Minneapolis, United States
- St Louis, United States
- Las Vegas, United States
- Nashua, United States
- Cherry Hill, United States
- Clementon, United States
- East Orange, United States
- Newark, United States
- Paramus, United States
- Brooklyn, United States
- Cedarhurst, United States
- Elmsford, United States
- Glen Oaks, United States
- Jamaica, United States
- New York, United States
- Rochester, United States
- Staten Island, United States
- Cincinnati, United States
- Columbus, United States
- Kettering, United States
- Oklahoma City, United States
- Allentown, United States
- DuBois, United States
- Norristown, United States
- Philadelphia, United States
- Charleston, United States
- Memphis, United States
- Austin, United States
- DeSoto, United States
- Houston, United States
- Irving, United States
- San Antonio, United States
- Richmond, United States
- Spokane, United States
- Calgary, Canada
- Red Deer, Canada
- Penticton, Canada
- Victoria, Canada
- Winnipeg, Canada
- Halifax, Canada
- Sydney, Canada
- Burlington, Canada
- Greater Sudbury, Canada
- Mississauga, Canada
- Orléans, Canada
- Toronto, Canada
- Windsor, Canada
- Montreal, Canada
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including AZD3480.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
